

Key Figures

| All figures are stated in millions of € according to IFRS, unless otherwise specified | 2022 | Δ in % | 2021 | 2020 | 2019 | 2018 |
|---------------------------------------------------------------------------------------|-------------------|--------|---------|---------|---------|---------|
| Order intake, sales revenue and earnings | | | | | | |
| Order intake | 4,007.3 | -6.1 | 4,267.9 | 2,836.3 | 1,939.5 | 1,662.5 |
| Sales revenue | 4,174.7 | 21.0 | 3,449.2 | 2,335.7 | 1,827.0 | 1,566.0 |
| Underlying EBITDA ¹ | 1,410.4 | 20.0 | 1,175.0 | 692.2 | 495.8 | 405.0 |
| Underlying EBITDA ¹ as a % of sales revenue | 33.8 | -0.3pp | 34.1 | 29.6 | 27.1 | 25.9 |
| Relevant net profit ² | 655.4 | 18.4 | 553.4 | 299.3 | 209.4 | 175.6 |
| Earnings per ordinary share ² (in €) | 9.57 | 18.4 | 8.08 | 4.37 | 3.06 | 2.56 |
| Earnings per preference share ² (in €) | 9.58 | 18.4 | 8.09 | 4.38 | 3.07 | 2.57 |
| Dividend per ordinary share (in €) | 1.43 ³ | 14.4 | 1.25 | 0.70 | 0.35 | 0.61 |
| Dividend per preference share (in €) | 1.44 ³ | 14.3 | 1.26 | 0.71 | 0.36 | 0.62 |
| Net worth and financial position | | | | | | |
| Cash flow from operating activities ⁴ | 734.2 | -15.9 | 873.2 | 511.5 | 377.2 | 244.5 |
| Capital expenditures as a % of sales | 12.5 | 0.7pp | 11.8 | 10.3 | 12.3 | 15.2 |
| Net debt | 2,375.3 | 37.1 | 1,732.7 | 1,883.9 | 1,014.0 | 959.5 |
| Ratio of net debt to underlying EBITDA ⁵ | 1.7 | | 1.5 | 2.6 | 2.0 | 2.4 |
| Equity ratio (in %) | 38.1 | 7.9pp | 30.2 | 30.8 | 38.1 | 38.5 |
| Total number of employees as of December 31 | | | | | | |
| | 15,942 | 15.3 | 13,832 | 10,637 | 9,036 | 8,125 |
| Bioprocess Solutions Division | | | | | | |
| Order intake | 3,122.7 | -10.4 | 3,483.5 | 2,238.1 | 1,457.6 | 1,233.7 |
| Sales revenue | 3,326.5 | 22.0 | 2,727.0 | 1,782.6 | 1,350.5 | 1,143.1 |
| Underlying EBITDA ¹ | 1,188.4 | 20.5 | 986.3 | 575.9 | 393.1 | 326.9 |
| Underlying EBITDA ¹ as a % of sales revenue | 35.7 | -0.5pp | 36.2 | 32.3 | 29.1 | 28.6 |
| Lab Products & Services Division | | | | | | |
| Order intake | 884.6 | 12.8 | 784.4 | 598.2 | 481.9 | 428.8 |
| Sales revenue | 848.2 | 17.4 | 722.2 | 553.0 | 476.5 | 423.0 |
| Underlying EBITDA ¹ | 222.0 | 17.6 | 188.8 | 116.3 | 102.7 | 78.1 |
| Underlying EBITDA ¹ as a % of sales revenue | 26.2 | 0.1pp | 26.1 | 21.0 | 21.6 | 18.5 |

1 Underlying = excluding extraordinary items

2 After non-controlling interest, adjusted for extraordinary items and amortization, as well as based on a normalized financial result and a normalized tax rate

3 Amounts suggested by the Supervisory Board and the Executive Board of Sartorius AG

4 Interest received are reported under cash flows from operating activities since fiscal 2022. The prior year figure was restated accordingly.

5 EBITDA includes underlying pro forma EBITDA contributed by acquisitions for this period

Sartorius Shares in Comparison to the DAX (indexed)

